OncoMatch/Clinical Trials/NCT06623136
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
Is NCT06623136 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ES102 and Toripalimab for non-small cell lung cancer.
Treatment: ES102 · Toripalimab — The aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
Without known EGFR mutation
Required: ALK wild-type
Without known...ALK fusion gene
Required: ROS1 wild-type
Without known...ROS1 fusion gene
Required: PD-L1 (CD274) overexpression (TPS ≥50% by 22C3 antibody IHC assay in the central laboratory)
PD-L1 TPS ≥50% by 22C3 antibody IHC assay in the central laboratory
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — concurrent or sequential
Previous failed concurrent or sequential treatment with systemic platinum-containing chemotherapy
Must have received: anti-PD-1/PD-L1 therapy — concurrent or sequential
Previous failed concurrent or sequential treatment with...PD-1/PD-L1 inhibitor therapy
Cannot have received: OX40 inhibitor
Any prior therapy targeting OX40
Cannot have received: bone marrow transplant
Prior allogeneic or autologous bone marrow transplant
Cannot have received: solid organ transplant
Prior...solid organ transplant
Lab requirements
Blood counts
adequate hematologic function as defined per protocol
Kidney function
adequate renal function as defined per protocol
Liver function
adequate hepatic function as defined per protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify